Medically Reviewed By:
Written By:
Last Modified April 8, 2022
This page features 6 Cited Research Articles
Fact Checked
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Reviewed is the nation’s most trusted mesothelioma resource

The Mesothelioma Center at has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.

Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.

More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.

About The Mesothelioma Center at

  • Assisting mesothelioma patients and their loved ones since 2006.
  • Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
  • A+ rating from the Better Business Bureau.
  • 5-star reviewed mesothelioma and support organization.
Learn More About Us


"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."
Mesothelioma patient’s daughter
  • Google Review Rating
  • BBB Review Rating
Read Our Testimonials
Jump To A Topic

What Lymphohistiocytoid Mesothelioma?

Despite the fact that this subtype is classified under the aggressive sarcomatoid cell type, these tumors tend to have a mix of epithelioid cells and inflammatory cells. Some patients diagnosed with this subtype of the disease may receive a prognosis, which is excessively optimistic and similar to that of an epithelial cell diagnosis..

One explanation for the small number of reported cases of this subtype is that it is often misdiagnosed as non-Hodgkin’s lymphoma or another condition. Studies show that symptoms and treatment options for this subtype are relatively similar to those of other pleural mesothelioma types. Its rarity leaves researchers few opportunities to study it, and there is little information for review. However, researchers and pathologists identified tumor characteristics that can aid in an accurate diagnosis.

Quick Facts About Lymphohistiocytoid Mesothelioma

  • First discovered in 1988
  • Characterized by dense bundles of inflammatory and immune cells
  • Sarcomatoid cell type, mixed with some epithelioid
  • May be misdiagnosed as lymphoma
  • Treated with surgery, chemotherapy and radiation therapy

Diagnosing Lymphohistiocytoid Mesothelioma

After surgeons take a sample of the tumor during a biopsy, the tissue is sent to a lab for a pathological study. Because of the large number of immune cells found in lymphohistiocytoid mesothelioma tumors, they are often mistaken for other cancers with similar cellular makeup: non-Hodgkin lymphoma, lymphoepithelial carcinoma, sarcomatoid carcinoma of the lung and ganglioneuroma (a tumor that forms in nerve fibers).

Common differential diagnoses of lymphohistiocytoid mesothelioma

  • Non-Hodgkin’s lymphoma
  • Hodgkin’s lymphoma
  • Lymphoepithelial carcinoma
  • Sarcomatoid carcinoma of the lung
  • Ganglioneuroma
  • Pleural-based thymic epithelial tumor
Find a Top Mesothelioma Doctor
Gain access to top mesothelioma doctors and get help scheduling appointments.

When doctors look at biopsied tissue under a microscope, histological studies reveal large, atypical polygonal to spindle-shaped histiocytoid cells. Mixed with these cells are white bloods cells (lymphocytes). Other signs of this tumor type are diffuse pleural thickening, small nodules throughout the pleura (the lining of the lung) and pleural effusion (a fluid buildup between pleural layers).

In this type of mesothelioma, histological studies and visual presentation of pleural-tissue changes are not usually enough to make a firm diagnosis. For a definitive diagnosis of lymphohistiocytoid mesothelioma, an immunohistochemical panel of antibodies for pathological staining is mandatory so that tumors can be differentiated from others that are similar.

In immunohistochemistry, pathologists add antibodies to tumor tissue and look for positive reactions in the tissue proteins. Each cancer has certain positive markers that doctors can look for under a microscope to make a more accurate diagnosis.

For lymphohistiocytoid tumors, the tissue is usually fixed in a block of paraffin, thinly sliced and mounted on a slide. In immunohistochemical studies, cytokeratin, vimentin, calretinin and CH5/6 were proteins strongly expressed by the histiocytoid cells found in the tumor. They are negative for lymphoid and macrophage markers. To differentiate it from other cancers such as lymphoepithelial-like carcinoma reaching the pleura or a pleural-based thymic epithelial tumor, the antibodies AE1/AE3 and calretinin are the most reliable for staining tissue samples.

Create a Free Personalized Mesothelioma Guide

2020 Mesothelioma Packet from the Mesothelioma Center

What is you or your loved one’s diagnosis?

Next Step Mesothelioma Guide

Customize Your Free Mesothelioma Guide

I would like more information about: Mesothelioma Guide

    Customize Your Free Mesothelioma Guide

    Do you need help finding a top specialist or getting a second opinion? Mesothelioma Guide

    Customize Your Free Mesothelioma Guide

    Where should we send your guide?

    By submitting, you agree to our privacy policy and disclaimer. Our Patient Advocates may contact you via phone, email and/or text.

    Symptoms, Treatment and Prognosis of Lymphohistiocytoid Mesothelioma

    Symptoms of lymphohistiocytoid mesothelioma are similar to other types of pleural mesothelioma and may include chest pain, weight loss and fatigue. Although information on treating this type of mesothelioma is limited, patients have generally been treated with surgery, chemotherapy and radiation therapy.

    Treatments for Lymphohistiocytoid Mesothelioma

    • Surgery
    • Chemotherapy
    • Radiation therapy

    Some of the earliest cases of lymphohistiocytoid mesothelioma that were described in 1988 reported no positive response to chemotherapy or radiation. The three patients treated survived for four months, five months and eight months. However, a 2007 study evaluating 22 cases showed much improvement in positive response to treatment and extended life span, with survival ranging between 32 and 40 months after diagnosis.

    In an encouraging individual case study, a spontaneous regression of the tumor was reported. Doctors surgically removed tumors from the patient, and 12 years after initial presentation he remained alive and well with no symptoms. In a small number of studies of this rare subtype, there were reports of survival of as much as six years after diagnosis. Some doctors suggest that the immune cells found in this tumor may have a connection to spontaneous regression.

    Get the Compensation You Deserve
    Healthy fish, vegetables and fruit
    Watch our Free Mesothelioma Nutrition Webinar
    Lab technician using a microscope in a lab
    Immunotherapy & Mesothelioma Clinical Trials

    Tell us what you think
    Did this article help you?
    How did this article help you?
    What about this article isn’t helpful for you?
    Did this article help you?

    Thank you for your feedback. Would you like to speak with a Patient Advocate?